Therapeutic or Preventive Procedure
Blooming Potential: BlossomHill Secures $100M Series B Funding for Small Molecule Cancer & Autoimmune Treatments
– BlossomHill Therapeutics, a biotech focusing on small-molecule drug design, has raised $100 million in a Series B financing round. – Led by Colt Ventures, the funding includes investors such as OrbiMed, Cormorant Asset Management, Vivo Capital, Hercules BioVentures Partners, and others. – Total capital raised by BlossomHill reaches $173 million after this round. – […]
Janux Shares Surge Over 200% on Promising Early Signs of PSA Response in Prostate Cancer Treatment
Prostate-Specific Antigen, Janux, JANX007, Malignant neoplasm of prostate
Johnson & Johnson Closes Bay Area R&D Facility, Plans New California Innovation Center
Research and Development, Johnson and Johnson, California, Central
Limited Role for Immuno-Oncology Despite Record Sales at Bavarian Nordic
Bavarian, Biological Markers
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s